Rhythm Pharmaceuticals, Inc.
RYTM
$50.97
$0.731.45%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | 41.83M | 33.25M | 29.08M | 25.97M | 24.23M |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 41.83M | 33.25M | 29.08M | 25.97M | 24.23M |
Cost of Revenue | 3.79M | 3.83M | 2.95M | 2.81M | 3.23M |
Gross Profit | 38.04M | 29.42M | 26.13M | 23.16M | 21.00M |
SG&A Expenses | 38.13M | 35.38M | 36.42M | 34.38M | 32.37M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 83.09M | 77.14M | 69.56M | 165.85M | 65.50M |
Operating Income | -41.26M | -43.89M | -40.48M | -139.89M | -41.27M |
Income Before Tax | -43.38M | -43.99M | -31.78M | -141.07M | -41.44M |
Income Tax Expenses | -90.00K | -344.00K | 479.00K | 300.00K | 196.00K |
Earnings from Continuing Operations | -43.29M | -43.64M | -32.26M | -141.37M | -41.63M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -43.29M | -43.64M | -32.26M | -141.37M | -41.63M |
EBIT | -41.26M | -43.89M | -40.48M | -139.89M | -41.27M |
EBITDA | -40.87M | -43.50M | -40.09M | -139.48M | -40.85M |
EPS Basic | -0.72 | -0.73 | -0.55 | -2.35 | -0.70 |
Normalized Basic EPS | -0.44 | -0.45 | -0.33 | -1.47 | -0.44 |
EPS Diluted | -0.72 | -0.73 | -0.55 | -2.35 | -0.70 |
Normalized Diluted EPS | -0.44 | -0.45 | -0.33 | -1.47 | -0.44 |
Average Basic Shares Outstanding | 61.60M | 61.22M | 61.01M | 60.14M | 59.21M |
Average Diluted Shares Outstanding | 61.60M | 61.22M | 61.01M | 60.14M | 59.21M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |